CoChat

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer

Open access
Chou, Angela, Froio, Danielle, Nagrial, Adnan M, Parkin, Ashleigh, Murphy, Kendelle J, Chin, Venessa T, Wohl, Dalia, Steinmann, Angela, Stark, Rhys, Drury, Alison, Walters, Stacey N, Vennin, Claire, Burgess, Andrew, Pinese, Mark, Chantrill, Lorraine A, Cowley, Mark J, Molloy, Timothy J, Waddell, Nicola, Johns, Amber, Grimmond, Sean M, Chang, David K, Biankin, Andrew V, Sansom, Owen J, Morton, Jennifer P, Grey, Shane T, Cox, Thomas R, Turchini, John, Samra, Jaswinder, Clarke, Stephen J, Timpson, Paul, Gill, Anthony J, Pajic, Marina · 2018 · Gut
Cited by 117

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Objective: Extensive molecular heterogeneity of pancreatic ductal adenocarcinoma (PDA), few effective therapies and high mortality make this disease a prime model for advancing development of tailored therapies. The p16-cyclin D-cyclin-dependent kinase 4/6-retinoblastoma (RB) protein (CDK4) pathway, regulator of cell proliferation, is deregulated in PDA. Our aim was to develop a novel personalised treatment strategy for PDA based on targeting CDK4. Design: Sensitivity to potent CDK4/6 inhibitor PD-0332991 (palbociclib) was correlated to protein and genomic data in 19 primary patient-derived PDA lines to identify biomarkers of response. In vivo efficacy of PD-0332991 and combination therapies was determined in subcutaneous, intrasplenic and orthotopic tumour models derived from genome-sequenced patient specimens and genetically engineered model. Mechanistically, monotherapy and combination therapy were investigated in the context of tumour cell and extracellular matrix (ECM) signalling. Prognostic relevance of companion biomarker, RB protein, was evaluated and validated in independent PDA patient cohorts (>500 specimens). Results: Subtype-specific in vivo efficacy of PD-0332991-based therapy was for the first time observed at multiple stages of PDA progression: primary tumour growth, recurrence (second-line therapy) and metastatic setting and may potentially be guided by a simple biomarker (RB protein). PD-0332991 significantly disrupted surrounding ECM organisation, leading to increased quiescence, apoptosis, improved chemosensitivity, decreased invasion, metastatic spread and PDA progression in vivo. RB protein is prevalent in primary operable and metastatic PDA and may present a promising predictive biomarker to guide this therapeutic approach. Conclusion: This study demonstrates the promise of CDK4 inhibition in PDA over standard therapy when applied in a molecular subtype-specific context.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-315144

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 117

Metadata

Authors
Chou, A., Froio, D., Nagrial, A. M., Parkin, A., Murphy, K. J., Chin, V. T., Wohl, D., Steinmann, A., Stark, R., Drury, A., Walters, S. N., Vennin, C., Burgess, A., Pinese, M., Chantrill, L. A., Cowley, M. J., Molloy, T. J., Waddell, N., Johns, A., Grimmond, S. M., Chang, D. K., Biankin, A. V., Sansom, O. J., Morton, J. P., Grey, S. T., Cox, T. R., Turchini, J., Samra, J., Clarke, S. J., Timpson, P., Gill, A. J., & Pajic, M.
Venue
Gut
Publisher
BMJ
Published
2017-10-28
Volume
67
Issue
12
Pages
2142-2155
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2766003958
Cited by
117
References
18
FWCI
5.92
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. https://app.cochat.ai/papers/10.1136/gutjnl-2017-315144
The paper
Chou, A., Froio, D., Nagrial, A. M., Parkin, A., Murphy, K. J., Chin, V. T., Wohl, D., Steinmann, A., Stark, R., Drury, A., Walters, S. N., Vennin, C., Burgess, A., Pinese, M., Chantrill, L. A., Cowley, M. J., Molloy, T. J., Waddell, N., Johns, A., . . . Pajic, M. (2018). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut. https://doi.org/10.1136/gutjnl-2017-315144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.